Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
48.23(c) 46.945(c) 46.93(c) 49.5(c) 49.93 Last
614 637 770 672 969 822 655 392 180 385 Volume
-2.96% -2.66% -0.03% +5.48% +0.87% Change
More quotes
Financials (USD)
Sales 2020 93,7 M - -
Net income 2020 -143 M - -
Net cash position 2020 377 M - -
P/E ratio 2020 -45,2x
Yield 2020 -
Sales 2021 171 M - -
Net income 2021 -150 M - -
Net cash position 2021 367 M - -
P/E ratio 2021 -43,3x
Yield 2021 -
Capitalization 6 722 M 6 722 M -
EV / Sales 2020 67,7x
EV / Sales 2021 37,2x
Nbr of Employees 453
Free-Float 94,4%
More Financials
Company
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. 
More about the company
Notations Surperformance© of Adaptive Biotechnologies Corporation
Trading Rating : Investor Rating :
More Ratings
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
10/16ADAPTIVE BIOTECHNOLOGIES CORP : Change in Directors or Principal Officers (form ..
AQ
10/14ADAPTIVE BIOTECHNOLOGIES : to Report Third Quarter Financial Results on November..
AQ
10/13ADAPTIVE BIOTECHNOLOGIES : to Report Third Quarter Financial Results on November..
AQ
10/13Adaptive Biotechnologies to Report Third Quarter Financial Results on Novembe..
GL
09/01Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Con..
GL
08/21ADAPTIVE BIOTECHNOLOGIES CORP : Other Events, Financial Statements and Exhibits ..
AQ
08/11ADAPTIVE BIOTECHNOLOGIES : to Present at the UBS Genomics 2.0 and Medtech Innova..
AQ
08/10ADAPTIVE BIOTECHNOLOGIES : 2Q Earnings Snapshot
AQ
08/10ADAPTIVE BIOTECHNOLOGIES : Management's Discussion and Analysis of Financial Con..
AQ
08/10ADAPTIVE BIOTECHNOLOGIES CORP : Results of Operations and Financial Condition, F..
AQ
08/10Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results
GL
08/10Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innov..
GL
08/07ADAPTIVE BIOTECHNOLOGIES : Receives Expanded FDA Clearance for the clonoSEQ Assa..
AQ
08/06ADAPTIVE BIOTECHNOLOGIES : Receives Expanded FDA Clearance for the clonoSEQ® Ass..
AQ
08/05ADAPTIVE BIOTECHNOLOGIES CORPORATION : half-yearly earnings release
More news
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION
08/05ADAPTIVE BIOTECHNOLOGIES CORPORATION : Veröffentlichung des Halbjahresergebnisse..
08/05ADAPTIVE BIOTECHNOLOGIES CORPORATION : publication des résultats semestriels
More news
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 54,50 $
Last Close Price 49,50 $
Spread / Highest target 27,3%
Spread / Average Target 10,1%
Spread / Lowest Target -15,2%
EPS Revisions
Managers
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Nancy L. Hill Senior Vice President-Operations
Chad M. Cohen CFO, Principal Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION65.44%6 722
EXACT SCIENCES CORPORATION18.62%16 473
GUARDANT HEALTH, INC.34.00%10 431
BGI GENOMICS CO., LTD.93.35%7 868
SEEGENE INC--.--%6 083
INVITAE CORPORATION180.60%5 965